Market Overview

UPDATE: Sterne Agee Resumes MedAssets at Buy on Improving Profitability

Related MDAS
Markets Edge Lower; Morgan Stanley Earnings Top Estimates
UPDATE: Bank Of America Downgrades MedAssets

In a report published Wednesday, Sterne Agee analyst Greg T. Bolan resumed coverage on MedAssets (NASDAQ: MDAS) with a Buy rating and $24.00 price target.

In the report, Sterne Agee noted, “We see profitability improving substantially as the company's GPO business continues to dominate market share and adoption of RCM IT applications improves following hospitals' race to achieve initial requirements under the CMS EHR incentive program. Re-initiate coverage with Buy rating and $24 price target.”

MedAssets closed on Tuesday at $17.31.

Posted-In: Greg T. Bolan Sterne AgeeAnalyst Color Initiation Analyst Ratings


Most Popular

Related Articles (MDAS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free